| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,145 | 5,240 | 30.04. | |
| 5,155 | 5,250 | 30.04. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 5,750 | 10.000 | |||
| 5,730 | 230 | |||
| 5,695 | 1.100 | |||
| 5,560 | 500 | |||
| 5,450 | 500 | |||
| 5,440 | 192 | |||
| 5,400 | 4.000 | |||
| 5,300 | 774 | |||
| 5,290 | 774 | |||
| 5,280 | 4.506 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/evt.htm [/URL] | ||||
| 1.496 | 5,210 | |||
| 22.010 | 5,185 | |||
| 774 | 5,175 | |||
| 774 | 5,165 | |||
| 300 | 5,050 | |||
| 2.000 | 4,990 | |||
| 6.000 | 4,900 | |||
| 3.000 | 4,800 | |||
| 285 | 4,640 | |||
| 2.000 | 4,510 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 38.639 | 0,584 | 22.576 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 30.04.2026 | 17:35:22 | 5,240 | 187.842 |
| 30.04.2026 | 17:29:57 | 5,215 | 186 |
| 30.04.2026 | 17:29:48 | 5,225 | 2 |
| 30.04.2026 | 17:29:31 | 5,220 | 300 |
| 30.04.2026 | 17:29:19 | 5,215 | 459 |
| 30.04.2026 | 17:29:00 | 5,205 | 43 |
| 30.04.2026 | 17:28:10 | 5,215 | 278 |
| 30.04.2026 | 17:27:42 | 5,210 | 400 |
| 30.04.2026 | 17:25:23 | 5,215 | 39 |
| 30.04.2026 | 17:25:23 | 5,215 | 114 |
| 30.04.2026 | 17:25:23 | 5,215 | 422 |
| 30.04.2026 | 17:22:58 | 5,205 | 78 |
| 30.04.2026 | 17:22:58 | 5,205 | 54 |
| 30.04.2026 | 17:22:58 | 5,205 | 33 |
| 30.04.2026 | 17:20:55 | 5,205 | 493 |
| 30.04.2026 | 17:19:21 | 5,213 | 400 |
| 30.04.2026 | 17:18:53 | 5,215 | 838 |
| 30.04.2026 | 17:17:46 | 5,210 | 302 |
| 30.04.2026 | 17:16:56 | 5,220 | 11 |
| 30.04.2026 | 17:15:09 | 5,210 | 808 |
| Tagesumsatz Xetra | +0,235 +4,70 % | 579.650 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16:38 | Eilmeldung am Abend: EVOTEC SE zündet den Kurs-Turbo! | 5 | Maximilian Berger | ||
| EVOTEC Aktie jetzt für 0€ handeln | |||||
| 16:30 | EILMELDUNG bei Evotec: Was große Adressen vor dem Wochenende bereits wissen - Meine Analyse im Detail | Hebelschein-Spekulant | |||
| Do | Evotec Receives Grants from Gates Foundation to Advance Tuberculosis Treatment | 38 | Contract Pharma | ||
| Do | EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | 502 | EQS Group (EN) | EQS Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| Do | Evotec erhält Fördermittel der Gates Stiftung | 56 | manager-magazin.de |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 12:38 | Moderna, Inc.: Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates | ACCESS Newswire | Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international marketsReports first quarter GAAP net loss of $(1.3) billion and GAAP EPS of $(3.40), including $0.9... ► Artikel lesen | |
| 15:20 | dpa-AFX-Überblick: UNTERNEHMEN vom 01.05.2026 - 15.15 Uhr | dpa-AFX | ROUNDUP 2/Apple: Deutlich höhere Kosten für Speicherchips - Aktie zieht an CUPERTINO - Der drastische Anstieg der Speicherchip-Preise trifft auch den für seine robuste Lieferkette bekannten iPhone-Konzern... ► Artikel lesen | |
| 13:42 | Moderna, Inc Q1 Loss Climbs | AFX News | WASHINGTON (dpa-AFX) - Moderna, Inc (MRNA) revealed Loss for its first quarter of -$1.343 billionThe company's earnings came in at -$1.343 billion, or -$3.40 per share. This compares with -$971... ► Artikel lesen | |
| Do | Recursion Pharmaceuticals: Recursion Announces Board Transition | GlobeNewswire (Europe) | Salt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson... ► Artikel lesen | |
| 13:10 | Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling | GlobeNewswire (Europe) | Positive Phase 1 data confirm MP0317's tumor-localized CD40 activation with a favorable safety profile in patients with advanced cancer typesPharmacokinetic profile of MP0317 well suited for combination... ► Artikel lesen |